RB
HRTX icon

Richmond Brothers’s Heron Therapeutics HRTX Stock Holding History

Richmond Brothers’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$765K Buy
1,792,319
+355,614
+25% +$285K 0.4% 72
2026
Q1 		$1.15M Buy
1,436,705
+864,587
+151% +$1M 0.77% 24
2025
Q4 		$744K Hold
572,118
– – 0.47% 25
2025
Q3 		$721K Buy
572,118
+17,649
+3% +$28K 0.46% 25
2025
Q2 		$1.15M Buy
554,469
+9,568
+2% +$19.5K 0.75% 21
2025
Q1 		$1.2M Sell
544,901
-97,438
-15% -$189K 0.76% 20
2024
Q4 		$983K Buy
642,339
+131,557
+26% +$213K 0.63% 22
2024
Q3 		$1.02M Buy
510,782
+154,224
+43% +$368K 0.63% 24
2024
Q2 		$1.25M Buy
356,558
+59,852
+20% +$184K 2.47% 8
2024
Q1 		$822K Hold
296,706
– – 1.52% 10
2023
Q4 		$504K Buy
296,706
+193,697
+188% +$213K 0.88% 13
2023
Q3 		$106K Buy
103,009
+60,604
+143% +$86.3K 0.2% 23
2023
Q2 		$49.2K Buy
+42,405
New +$75.6K 0.08% 22

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Richmond Brothers's HRTX Position: Q2 2026 in Review

Richmond Brothers increased its Heron Therapeutics (HRTX) stake by 25% in Q2 2026, buying an estimated $285K and bringing the position to 1,792,319 shares worth $765K. The position accounts for 0.4% of the portfolio, ranked #72.

Richmond Brothers first reported a position in HRTX in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.25M in Q2 2024. 162 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Richmond Brothers held 1,792,319 shares of Heron Therapeutics worth $765K as of Q2 2026.
  • Richmond Brothers bought 355,614 Heron Therapeutics shares in Q2 2026, an estimated $285K.
  • Heron Therapeutics made up 0.4% of Richmond Brothers's portfolio in Q2 2026, its #72 holding.
  • Richmond Brothers first reported a position in Heron Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • Richmond Brothers's Heron Therapeutics position peaked at $1.25M in Q2 2024.
  • 162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Richmond Brothers's 13F filing for Q2 2026, filed 11 Aug 2026.